TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02463305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: 21 grams creatine monohydrate total per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: 21 grams creatine monohydrate total per day
Study: NCT06433518

Intervention type: DRUG
Intervention: recombinant hCG
Description: Experimental Group: Final oocyte triggering will be performed when the follicle or follicles measure between 13-16 mm.~Control Group: Final oocyte triggering will be performed when the follicle or follicles measure greater than 17 mm.~All triggers will be administered uniformly with 6500 units of recombinant hCG and 0,2 mg triptorelin injections.~The primary outcome of the study will be the number of mature oocytes. Secondary outcomes will include fertilization rates, embryo counts, and implantation rates.~Primary and secondary outcomes will be compared between the two groups.
Study: NCT02463305

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 grams of dextrose dissolved in 500mL water, taken three times daily
Study: NCT06222541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudges in Web-Based Supermarket
Description: While shopping in the web-based supermarket, participants assigned to the nudge arm will see retail nudges to discourage sugary drink purchases and promote healthier substitutes.
Study: NCT04792359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equinometer
Description: Measurement of dorsiflexion of the ankle will be reproduced three times on each ankle in two positions, with a force applied
Study: NCT06443788

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: transperineal ultrasound
Description: The following measurement will be recorded:~1. Amniotic fluid pooling assessment will be performed in sagittal and transverse planes. ,~   * Images will be evaluated for appearance of accumulated hypoechogenic fluid around cervix. Whenever collection is spotted, three largest dimensions of fluid will be measured (length, width, depth).~  * Fluid accumulations around the cervix that are clearly demarcated from surrounding tissues will be considered positive.~2. Cervical length: it will be measured between the internal os point to the external os point below. Cervical dilatation will be measured in a transverse plane from inner to inner.~3. Presence of fetal part prolapse and/or cord prolapse
Study: NCT06651294

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Neorenal Forte
Description: This specialized formulation of phytotherapeutic extracts consists of proprietary Betula pendula leaves dry extract, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens. The product contains supplementary ingredients: microcrystalline cellulose, povidone, magnesium stearate, colorant film (brilliant blue FCF, iron dioxide).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product will be identical to the active form and will have the same composition but without the proprietary extract from Betula pendula, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens.
Study: NCT05322837

Intervention type: OTHER
Intervention: Clinical and technological-aided assessments and questionnaires
Description: Assessments and questionnaires related to upper limb function and quality of life will be used
Study: NCT06238752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Combined With Tislelizumab and Chemotherapy
Description: apatinib (250 mg, qd, d1-14), tislelizumab(200 mg d1), and oxaliplatin (130 mg/m2, d1) plus oral capecitabine (1000 mg/m2, bid, d1-14) every 3 weeks
Study: NCT05075213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management (deposit contract)
Description: Participants will deposit $30 of their own money to play QuitBet. Participants will submit a CO test once per day between the hours of noon and 11:59pm. Participants whose CO test is 6ppm or lower (indicating no smoking) on at least 24 of 26 days between day 3-28 of the game will be declared winners and split the pot of deposited money. Participants who submit at least 21 CO tests, regardless of the result, will be entered into a raffle to win a prize worth $75.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: contingency management (deposit contract)
Description: Participants will deposit $30 of their own money to play QuitBet. Participants will submit a CO test once per day between the hours of noon and 11:59pm. Participants whose CO test is 6ppm or lower (indicating no smoking) on at least 24 of 26 days between day 3-28 of the game will be declared winners and split the pot of deposited money. Participants who submit at least 21 CO tests, regardless of the result, will be entered into a raffle to win a prize worth $75.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: leaderboard and social feed
Description: Participants will have access to a discussion board on which participants can post and respond to messages to each other. Also, a game host will post educational information about smoking cessation and serve as a discussion moderator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation resource list
Description: Participants will have access to a list of smoking cessation resources
Study: NCT05506436

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evident 3
Description: It consists of brief 5-minute counselling on general physical activity recommendations and explaining the plate method for a balanced diet. Also, it includes the Evident 3 application, which is a daily dietary log that provides information on calories and diet composition and shows a reminder of the 10000 steps/day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evident 3
Description: It consists of brief 5-minute counselling on general physical activity recommendations and explaining the plate method for a balanced diet. Also, it includes the Evident 3 application, which is a daily dietary log that provides information on calories and diet composition and shows a reminder of the 10000 steps/day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation strategy
Description: Four sessions have been designed to obtain the implementation strategy:~First session: Presentation of the Evident 3 application and its results in clinical trials. Training in the use of the application and identification of possible areas for improvement.~Second session: Presentation of evidence-based practices on the management of obesity in Primary Care. Consensus selection of those related to health promotion and mHealth. Sharing of possible lines of improvement of the care offered in the practice.~Third session (optional): Intervention on those components (coherence, cognitive participation, collective action and reflective follow-up) of the NOMAD questionnaire, if very low scores are obtained.~Fourth session: Brainstorming on possible strategies for the implementation of the Evident 3 intervention. Analysis and evaluation of these strategies and determination of a common strategy for their implementation.
Study: NCT06339320

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic Sleeve Gastroplasty (ESG)
Description: The ESG procedure uses the Apollo OverStitch endoscopic suturing device, which has received FDA authorization as a minimally invasive procedure to facilitate weight loss for adults with who have been unable to lose weight or maintain weight loss through more conservative measures such as diet and exercise. This procedure involves endoscopic suturing to reduce the volume of the stomach endoscopically by approximately 70% to 80% its original size. Using the Apollo OverStitch or APOLLO ESG and ESG SX Systems, the ESG procedure is performed be folding the stomach in on itself (endoscopically) and placing full-thickness sutures through the wall of the stomach to maintain this narrow, smaller size. Following the procedure, the new stomach appears similar to the surgical sleeve stomach, although the procedure is considered less invasive with fewer complications compared to a surgical sleeve gastrectomy.

Intervention type: DEVICE
Group type: OTHER
Intervention: Apollo OverStitch endoscopic suturing device
Description: Apollo ESG is the first and only device to be authorized by the FDA to perform the ESG procedure to facilitate weight loss in patients with obesity (BMI 30 to 50 kg/m2). The FDA identifies this generic type of device as an Endoscopic suturing device for altering gastric anatomy for weight loss.
Study: NCT05486897

Intervention type: OTHER
Intervention: None, pure observational study
Description: None, pure observational study
Study: NCT05720442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tangweian Recipe
Description: The Tangweian recipe is a combination of several Chinese herbs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosapride Citrate
Description: The mosapride citrate tablets will be administrated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride Citrate
Description: The mosapride citrate tablets will be administrated.
Study: NCT05796804

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERECTOR SPINAE PLANE BLOCK
Description: ULTRASOUND GUIDED - ROPIVACAINE 30 ml 0.5%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peng block + lateral femoral cutaneous nerve block
Description: ULTRASOUND GUIDED - ROPIVACAINE 20 ml 0.5% + 10 ml 0.5%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: bupivacaine 0.5% 2.2 ml

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: bupivacaine 0.5% 2.2 ml
Study: NCT05776914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Fecal Microbiota Transplantation
Description: Single fecal microbiota transplantation using 50 gm of freeze-thawed donor stool
Study: NCT06598332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine
Description: Patients will be treated with 5 azacytidine at a dose of 32 mg/m2 SQ or IV. The investigators aim to start AZA on Day 1 of steroids but it can be started up to 72 hours after steroids are started . Patients will be premedicated with antiemetics.~Patients must receive steroids at a minimum dose of prednisone 2 mg/kg/day PO (or methylprednisolone 1.6 mg/kg/day IV) divided into 1-2 daily doses as therapy for acute GVHD. For patients that weigh over 100 kg, maximal starting dose of prednisone will be 200 mg (or methylprednisolone-equivalent).~Steroid Taper for responding patients (Prednisone/Methylprednisolone) Days 1-5 2 mg/kg/day (taper cannot start until 3 days after enrollment) Days 6-10 1.5 mg/kg/day Day 11-15 1.0 mg/kg/day Days 16-20 0.5 mg/kg/day Days 21-28\* 0.25 mg/kg/day Days 29-56 Gradual further taper with a goal of reaching \< 0.2 mg/kg/day of prednisone (or \< 0.16 mg/kg/day of methylprednisolone) by Day 56.
Study: NCT05776914

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Fecal Microbiota Transplantation
Description: Single fecal microbiota transplantation using 50 gm of stool collected from the same individual
Study: NCT06614036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Byfavo 20 mg powder for solution for injection, remimazolam. Each vial contains remimazolam besylate equivalent to 20 mg remimazolam. Concentration after reconstitution: 2.5 mg/ml.
Study: NCT04861558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: Injection of 250-850 mg/m2.
Study: NCT04861558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Injection of 360 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Injection of 460 mg/m2
Study: NCT05356741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX-818
Description: Administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX-818
Description: Administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX-818
Description: Administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX-818
Description: Administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as IV infusion
Study: NCT05978908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FC-12738
Description: Retro enversio pentapeptide of thymopentin
Study: NCT04190212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training + standard care
Description: HIIT sessions will include: (1) warm-up for 2 minutes at 50% of peak power output (PPO); (2) 2 x 8-minute interval training blocks (total: 16 minutes) of 30-seconds at 80-100% of PPO interspersed with 30-seconds active recovery, 4 minutes of recovery will be permitted between the blocks; and, (3) 2 minute cool-down at 25% of PPO after the last 30-second exercise bout.
Study: NCT05043246

Intervention type: BIOLOGICAL
Intervention: SARS-COV-2 VACCINE
Description: the antibody titer and adverse reactions were observed.
Study: NCT05978908

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: placebo
Study: NCT06614036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 1mg/ml, solution for injection / infusion. Each 5ml ampoule contains 5mg midazolam. Concentration: 1mg/ml.
Study: NCT04865185

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine spray 100mg/ml
Description: Topical application

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Description: Topical application
Study: NCT04705441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART 2
Description: Participants receiving the SMART intervention will participate in 8 group-format 45-60 minute sessions (up to 10 participants per group), which will be collaboratively delivered over Zoom by a Nurse Educator and a Peer Educator with epilepsy. Telephone call-in and supplemental printed materials will be available for those who do not have internet access. The initial group session portion of SMART will be completed over 10-12 weeks. Educational components address the challenges imposed by epilepsy and comorbidity, as well as problem-identification and goal-setting, while Peer Educators and the group format address adherence, social support/social isolation, and self-efficacy. Following group sessions, participants will have 3 brief (no more than 15 minutes) monthly web-based or telephone maintenance sessions conducted by the Nurse Educator. Telephone sessions will address on-going issues of epilepsy self-management, including treatment adherence.
Study: NCT04934306

Intervention type: OTHER
Intervention: Nasometry
Description: Repetition of several stimuli (syllables, sentences ) in the microphones of the Nasometer

Intervention type: OTHER
Intervention: Nasometry
Description: Repetition of several stimuli (syllables, sentences ) in the microphones of the Nasometer
Study: NCT05969275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord-derived human mesenchymal stromal cells
Description: Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo, with excipients
Study: NCT06678542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 tablet
Description: GP681 tablet, 20 mg, single oral dose in each Group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 tablet
Description: GP681 tablet, 20 mg, single oral dose in each Group.
Study: NCT06554756

Intervention type: OTHER
Group type: OTHER
Intervention: Saliva, serum and GCF sampling
Description: Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Gingival crevicular fluid (GCF) samples were taken from the vestibular, mesial, and distal surfaces of a single-rooted tooth with standard paper strips (Periopaper, Oraflow Inc., Plainview, NY, USA). Saliva, GCF and serum were then stored at -80 °C until analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva, serum and GCF sampling
Description: Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Gingival crevicular fluid (GCF) samples were taken from the vestibular, mesial, and distal surfaces of a single-rooted tooth with standard paper strips (Periopaper, Oraflow Inc., Plainview, NY, USA). Saliva, GCF and serum were then stored at -80 °C until analysis.
Study: NCT06678542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 Powder for Oral Suspension
Description: GP681 Powder for Oral Suspension, 20 mg, single oral dose in each Group.
Study: NCT04652284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifabutin
Description: 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifabutin
Description: 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1000 mg
Study: NCT06547918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod 5 SA2.0 System
Description: The Omnipod 5 SA2.0 System provides automated insulin delivery based on Continuous Glucose Monitoring (CGM) values.
Study: NCT04868370

Intervention type: OTHER
Intervention: Assessment of the upper limb (VPIT + PPIT)
Description: Assessment of the upper limb sensorimotor function (VPIT and PPIT)
Study: NCT06197542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Technique
Description: active TrP was identified, and sustained and constant pressure was applied .for stretching of the SCM muscle, the patient performed contralateral lateral flexion and ipsilateral rotation of the head to achieve stretching, for trapezius the therapist performed lateral flexion of the neck.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: The therapist applied IASTM strokes for 20 seconds parallel to muscle fibers, followed by strokes for 20 seconds perpendicular to muscle fibers with the tool held at a 45° to the skin. .
Study: NCT05994313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Habitual potato consumption
Description: Potatoes are to be consumed in the evening meal, every evening for 12-weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Habitual non-nutrient-dense staple consumption
Description: White rice, white pasta or white couscous are to be consumed in the evening meal, every evening for 12-weeks.
Study: NCT06619821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotiaonl skill enhancement
Description: This intervention combines online material with practical, emotion-focused activities. Participants will receive training on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotiaonl skill enhancement
Description: This intervention combines online material with practical, emotion-focused activities. Participants will receive training on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.
Study: NCT05498818

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synaquell
Description: 7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synaquell
Description: 7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
Study: NCT06619821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCE promotion
Description: The intervention requires parents to complete a weekly parent-child interaction task designed to foster positive childhood experiences. Parents will engage in structured activities with their children and document the interactions. Each week, they are expected to upload a report.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.